Compare Boston Scientific Corporation (BSX) vs Pfizer Inc (PFE) Price & Performance

Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.

BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.

Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.

The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.